Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline

Conduit Pharmaceuticals announces new addition to its autoimmune pipeline, underscored by composition of matter patent filing to strengthen its competitive position This new asset, CDT1656, combines AZD1656 with a second known-compound that has demonstrated immune-modulating effects across multiple autoimmune conditions, enhancing its therapeutic potentialThe addition of CDT1656 and the supporting composition of matter patent filing highlight Conduit’s commitment to building a robust asset portfolio, positi ...